

Jui-Chen Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1547245/publications.pdf>

Version: 2024-02-01

11
papers

241
citations

1478505

6
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

347
citing authors

#	ARTICLE	IF	CITATIONS
1	The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. <i>Value in Health</i> , 2019, 22, 157-160.	0.3	124
2	Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. <i>Journal of Medical Economics</i> , 2012, 15, 1139-1148.	2.1	36
3	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2020, 156, 561-567.	1.4	21
4	Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. <i>Cancer</i> , 2019, 125, 4399-4406.	4.1	16
5	Caregiver Preferences for the Treatment of Males with Fragile X Syndrome. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2016, 37, 71-79.	1.1	14
6	Patient Preferences for Surgical Treatment of Knee Osteoarthritis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 2022-2031.	3.0	10
7	Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008797.	3.9	7
8	Patient preferences pertaining to treatment options for drug-resistant focal epilepsy. <i>Epilepsy and Behavior</i> , 2022, 127, 108529.	1.7	5
9	Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. <i>JCO Oncology Practice</i> , 2021, 17, e1639-e1648.	2.9	4
10	Is Easier Better Than Harder? An Experiment on Choice Experiments for Benefit-Risk Tradeoff Preferences. <i>Medical Decision Making</i> , 2021, 41, 222-232.	2.4	2
11	The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. <i>Gynecologic Oncology</i> , 2021, 162, 440-446.	1.4	2